EA
MACK

Edge Advisors’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

Edge Advisors’s Portfolio MACK Stock Details MACK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		$1K Hold
318
– – ﹤0.01% 819
2018
Q1 		$2K Hold
318
– – ﹤0.01% 823
2017
Q4 		$2K Buy
+318
New +$2.96K ﹤0.01% 878

Other funds holding MACK

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
TCIM
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return
WIM
Wittenberg Investment Management Carlisle, Massachusetts $269M AUM 28.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Edge Advisors's MACK Position: Q2 2018 in Review

Edge Advisors held its Merrimack Pharmaceuticals, Inc. (MACK) position steady in Q2 2018 at 318 shares worth $1K. The position accounts for ﹤0.01% of the portfolio, ranked #819.

Edge Advisors first reported a position in MACK in Q4 2017 and has held it in 3 quarters since. The position peaked at $2K in Q1 2018. 76 funds tracked by Wall St. Rank hold MACK as of Q2 2018.

  • Edge Advisors held 318 shares of Merrimack Pharmaceuticals, Inc. worth $1K as of Q2 2018.
  • Edge Advisors left its Merrimack Pharmaceuticals, Inc. share count unchanged in Q2 2018.
  • Merrimack Pharmaceuticals, Inc. made up ﹤0.01% of Edge Advisors's portfolio in Q2 2018, its #819 holding.
  • Edge Advisors first reported a position in Merrimack Pharmaceuticals, Inc. in Q4 2017 and has held it in 3 quarters since.
  • Edge Advisors's Merrimack Pharmaceuticals, Inc. position peaked at $2K in Q1 2018.
  • 76 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q2 2018.

Based on Edge Advisors's 13F filing for Q2 2018, filed 14 Aug 2018.